Kengo Azushima

Assistant Professor

Yokohama City University Graduate School of Medicine

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kengo Azushima is an Assistant Professor at the Yokohama City University Graduate School of Medicine in Japan. His research focuses on hypertension, renal fibrosis, and the molecular mechanisms underlying kidney diseases, as evidenced by his recent publications. He has contributed significantly to the understanding of the renin-angiotensin system and its implications for various health conditions, particularly in patients with cardiovascular and renal complications.

Articles (20)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Go Noguchi

Yokohama National University

JAPAN

View details

Shunichiro Tsukamoto

Yokohama National University

JAPAN

View details

Kazushi Uneda

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kengo Azushima

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Keratinocyte-specific angiotensin II receptor-associated protein deficiency exacerbates angiotensin II-dependent hypertension via activation of the skin renin-angiotensin system

Leucine-rich alpha-2-glycoprotein 1 deficiency suppresses ischemia-reperfusion injury-induced renal fibrosis.

SETD2 regulates SLC family transporter-mediated sodium and glucose reabsorptions in renal tubule

Proteomic serum profiles before and after lipoprotein apheresis in patients with peripheral artery disease with ulceration.

Clinical Course and Factors Correlated with Severe Morbidity and Mortality in Patients with Coronavirus Disease 2019 Undergoing Maintenance Dialysis in Kanagawa, Japan.

Behcet's disease presenting as malignant hypertension induced by renovascular hypertension.

Lipoprotein Apheresis Alleviates Treatment-Resistant Peripheral Artery Disease Despite the Normal Range of Atherogenic Lipoproteins: The LETS-PAD Study.

Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients

Effects of a High-Protein Diet on Kidney Injury under Conditions of Non-CKD or CKD in Mice

Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis.

Angiotensin II type 1 receptor-associated protein deletion combined with angiotensin II stimulation accelerates the development of diabetic kidney disease in mice on a C57BL/6 strain.

Association between serum irisin levels and blood pressure in patients undergoing hemodialysis.

miR-125a-5p/miR-125b-5p contributes to pathological activation of angiotensin II-AT1R in mouse distal convoluted tubule cells by the suppression of Atrap.

Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis

Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients

Impact of the COVID-19 pandemic on physical and psychological activities in elderly patients with hypertension.

Angiotensin II type-1 receptor-associated protein interacts with transferrin receptor-1 and promotes its internalization.

SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.

Collaborators (3)

Go Noguchi

Shunichiro Tsukamoto

Kazushi Uneda

Make your next move.